In et al. analyzed 15 cSCC patients treated with a PD-1 inhibitor (cemiplimab, pembrolizumab, or nivolumab) and found higher TMB levels in responders vs. non-responders (median: 60 vs. 9 mut/Mb) [22]. This evidence concerns the gene PDCD1 and skin squamous cell carcinoma.